Rasagiline treats Parkinson's disease, but its mechanism may be more complex than we thought.
In short: Rasagiline is a standard treatment for Parkinson's disease, primarily known for inhibiting the enzyme MAO-B to boost dopamine. Yet, recent research suggests this pathway might not be the whole story. As we uncover how this drug interacts with brain chemistry, our understanding of its therapeutic benefits continues to evolve.
Rasagiline, marketed as Azilect, is a selective monoamine oxidase B (MAO-B) inhibitor approved for Parkinson's disease in the European Union in 2005 and the United States in 2006. By irreversibly binding to MAO-B, the drug prevents the breakdown of dopamine, helping to compensate for the loss of dopamine-producing neurons. Unlike its predecessor selegiline, rasagiline does not metabolize into amphetamine-like compounds, which avoids certain psychostimulant side effects. It is typically prescribed as a 1 mg daily oral dose.
The clinical profile of rasagiline is nuanced. While it effectively manages motor symptoms, attempts to prove it could slow disease progression—specifically through the TEMPO and ADAGIO trials—were rejected by the FDA in 2011. The agency noted that the results failed to demonstrate neuroprotection, partly because the 2 mg dose did not outperform the 1 mg dose, defying standard pharmacological expectations. Furthermore, while it is often well-tolerated, it carries risks of orthostatic hypotension and potential interactions with serotonergic drugs, necessitating a 14-day washout period.
Recent scientific findings have challenged the traditional understanding of how MAO-B inhibitors function. A 2021 study revealed that in rodents, MAO-A, not MAO-B, is primarily responsible for striatal dopamine breakdown. Instead, MAO-B appears to mediate the synthesis of GABA, an inhibitory neurotransmitter, from putrescine. This discovery suggests that rasagiline's efficacy might stem from modulating GABA levels or other pathways, such as binding to the protein α-synuclein or the enzyme GAPDH. Additionally, its major metabolite, (R)-1-aminoindan, shows independent neuroprotective properties, further complicating the drug's pharmacological narrative.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Rasagiline
To cite this card, link to https://intellectplus.co.uk/app/technology-rasagiline.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Medicines · More in Health · Latest · A–Z · All topics